1082503-77-2

Basic information

• Product Name: [1-(2-Hydroxy-2-Methyl-propyl)pyrazol-4-yl]boronic acid pinacol ester
• Synonyms: [1-(2-Hydroxy-2-Methyl-propyl)pyrazol-4-yl]boronic acid pinacol ester;2-Methyl-1-(4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propan-2-ol;2-methyl-1-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]propan-2-ol;[1-(2-Hydroxy-2-Methyl-propyl)pyrazol-4-yl]boronic acid;1-(2-Hydroxy-2-methylprop-1-yl)-1H-pyrazole-4-boronicacid,pinacolester;2-Methyl-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]propan-2-ol
• CAS NO: 1082503-77-2
• Molecular Formula: C13H23BN2O3
• Molecular Weight: 266.14432
• Mol File: 1082503-77-2.mol
• Article Data: 29

Chemical Properties

• Boiling Point: 393.3±22.0 °C(Predicted)
• Appearance: /
• Density: 1.07±0.1 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 14.61±0.29(Predicted)
• CAS DataBase Reference: [1-(2-Hydroxy-2-Methyl-propyl)pyrazol-4-yl]boronic acid pinacol ester(CAS DataBase Reference)
• NIST Chemistry Reference: [1-(2-Hydroxy-2-Methyl-propyl)pyrazol-4-yl]boronic acid pinacol ester(1082503-77-2)
• EPA Substance Registry System: [1-(2-Hydroxy-2-Methyl-propyl)pyrazol-4-yl]boronic acid pinacol ester(1082503-77-2)

Safety Data

• Hazardous Substances Data: 1082503-77-2(Hazardous Substances Data)

Usage

General Description

"[1-(2-Hydroxy-2-Methyl-propyl)pyrazol-4-yl]boronic acid pinacol ester" is a unique chemical compound. It contains organic elements often used in the fields of pharmaceuticals and biotechnology. The boronic acid pinacol ester functional group in the compound suggests that it may have certain properties such as being a catalyst or possibly participating in coupling reactions, which are important processes in medicinal chemistry for creating new bonds. Its framework features a pyrazole ring, a class of organic compounds with a five-membered aromatic ring containing two nitrogen atoms, which is common in many pharmaceutical products. Moreover, the presence of a hydroxy and methyl group indicates that this chemical might possess alcohol and alkane-like characteristics respectively. However, the specific properties, uses, and safety measures would require further experimental data and exploration.

Upstream product

• 269410-08-4 pyrazole-4-boronic acid pinacol ester 
• 558-42-9 3-chloro-2-methylpropan-2-ol 
• 558-30-5 2-methyl-1,2-epoxypropane 

Downstream Products

• 1613300-97-2 3,5-difluoro-4-[1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]phenol 
• 1613300-99-4 1-{4-[2,6-difluoro-4-(4,4,5,5-tetramethyl-[1,3,2]-dioxaborolan-2-yl)phenyl]pyrazol-1-yl}-2-methylpropan-2-ol 
• 1613300-98-3 3,5-difluoro-4-(1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl)phenyl trifluoromethanesulfonate 

Relevant articles and documents

Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor

The receptor tyrosine kinase Axl plays important roles in promoting cancer progression, metastasis, and drug resistance and has been identified as a promising target for anticancer therapeutics. We used molecular modeling-assisted structural optimization starting with the low micromolar potency compound 9 to discover compound 13c, a highly potent and orally bioavailable Axl inhibitor. Selectivity profiling showed that 13c could inhibit the well-known oncogenic kinase Met with equal potency to its inhibition of Axl superfamily kinases. Compound 13c significantly inhibited cellular Axl and Met signaling, suppressed Axl- and Met-driven cell proliferation, and restrained Gas6/Axl-mediated cancer cell migration or invasion. Furthermore, 13c exhibited significant antitumor efficacy in Axl-driven and Met-driven tumor xenograft models, causing tumor stasis or regression at well-tolerated doses. All these favorable data make 13c a promising therapeutic candidate for cancer treatment.

N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF

An N-(azaaryl)cyclolactam-1-carboxamide derivative having a structure of formula (I), a preparation method therefor, and a use thereof are disclosed in the application. Each substituent are defined in the specification and claims. The series of compounds of the application can be widely applied in the preparation of drugs for treating cancer, tumor, autoimmune disease, metabolic disease or metastatic disease, particularly for treating ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic disease, neurodegenerative disease, primary tumor site metastasis or osseous metastasis cancer, and are expected to be developed into a new generation of CSF-1R inhibitor drugs.

2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES

Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.